Presentation of a Novel Model for Evaluation of Commercialization of Research and Development: Case Study of the Pharmaceutical Biotechnology Industry

Background and scope: The current situation in Iran suggests a good basis for advancement in biotechnology industries because the patents for many hi-tech medicines registered in developed countries are ending. Biosimilar and technology-oriented companies without patents will have the opportunity to enter the biosimilar market and move toward innovative initiatives. The present research proposed a model by which one can evaluate commercialization of achievements obtained from research with a focus on the pharmaceutical biotechnology industry.
This is a descriptive-analytic study where mixed methodology is followed by a heuristic approach. The statistical population was experts active in pharmaceutical biotechnology and those at universities and research centers in Iran. Structural equations were employed in this research.
Findings: The results indicate that there are three effective layers within commercialization in the proposed model. These are a general layer (factors associated with management, human capital, legal infrastructure, communication infrastructure, technical and executive infrastructures, and financial factors), industrial layer (internal industrial factors and pharmaceutical industry factors), and a third layer that included national and international aspects. These layers comprise 6 domains, 21 indices, 41 dimensions, and 126 components.
Compilation of these layers (general layer, industrial layer, and national and international aspects) can serve commercialization of research and development as an effective evaluation package.